News

In This Section

Recent Press Releases

January 9, 2017

Company Reports Preliminary Total Net Product Sales Expected to be Between $150 million and $152 million, Exceeding High End of Prior Guidance

Global Expansion Plans for Metreleptin Opportunity Underway

December 22, 2016

If approved, metreleptin would be the first medication available in the EU to treat generalized and partial lipodystrophies

More than 100 patients are currently treated with metreleptin via a compassionate use program in Europe

December 16, 2016

Vancouver, BC, December 16, 2016 - Novelion Therapeutics (NASDAQ: NVLN) (TSX: NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first commercial shipment of JUXTAPID® (lomitapide) to a patient in Japan. In September 2016, JUXTAPID was approved by Japan’s Ministry of Health, Labor & Welfare (MHLW) for patients with homozygous familial hypercholesterolemia (HoFH).

Pages